Yamashita J, Horiuchi S, Kimura M, Nishimura R, Akagi M
Jpn J Cancer Res. 1986 Feb;77(2):177-81.
To examine whether plasminogen activator reflects the functional state of estrogen receptors in human breast cancer, the enzyme activities were determined in extracts prepared from 160 breast cancer specimens and compared on qualitative and quantitative bases with the levels of steroid receptors, such as cytoplasmic estrogen receptor (ERC), progesterone receptor (PgR) and nuclear estrogen receptor (ERN). With any receptor, plasminogen activator activity was significantly higher in receptor-positive tumors than in receptor-negative tumors. When these breast tumors were categorized into 8 groups in terms of combinations of receptor status, breast cancers which were positive for all these receptors were found to contain the highest plasminogen activator activity. Furthermore, quantitative analyses demonstrated positive correlations of the enzyme activity with either ERC content (correlation coefficient +0.37, P less than 0.001) or PgR content (correlation coefficient +0.45, P less than 0.001). These results strongly suggest that plasminogen activator can be used as an effective functional marker for hormone dependence in human breast cancer.
为了研究纤溶酶原激活剂是否反映人类乳腺癌中雌激素受体的功能状态,我们测定了从160例乳腺癌标本中提取的酶活性,并在定性和定量的基础上与类固醇受体水平进行了比较,这些类固醇受体包括细胞质雌激素受体(ERC)、孕激素受体(PgR)和细胞核雌激素受体(ERN)。对于任何一种受体,受体阳性肿瘤中的纤溶酶原激活剂活性均显著高于受体阴性肿瘤。当根据受体状态的组合将这些乳腺肿瘤分为8组时,发现所有这些受体均为阳性的乳腺癌含有最高的纤溶酶原激活剂活性。此外,定量分析表明酶活性与ERC含量(相关系数+0.37,P<0.001)或PgR含量(相关系数+0.45,P<0.001)均呈正相关。这些结果强烈表明,纤溶酶原激活剂可作为人类乳腺癌激素依赖性的有效功能标志物。